Focused On-demand Library for Serine/threonine-protein kinase 10

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Lymphocyte-oriented kinase

Alternative UPACC:

O94804; A6ND35; B2R8F5; B3KMY1; Q6NSK0; Q9UIW4


Serine/threonine-protein kinase 10, also known as Lymphocyte-oriented kinase, plays a pivotal role in the regulation of lymphocyte migration. It achieves this by phosphorylating MSN and potentially PLK1, alongside mediating the phosphorylation of ERM proteins such as MSN. This kinase acts as a negative regulator of MAP3K1/MEKK1 and may serve as a cell cycle regulator by acting as a polo kinase kinase, suggesting its involvement in phosphorylating PLK1.

Therapeutic significance:

Given its involvement in Testicular germ cell tumor (TGCT), a prevalent malignancy in males, understanding the role of Serine/threonine-protein kinase 10 could unveil novel therapeutic strategies. Its regulatory functions in cell migration and cycle may offer insights into targeting TGCT progression.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.